CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites … [Read more…]
First non-antibiotic macrolide to go into clinical development – targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway REYKJAVIK, Iceland–(BUSINESS WIRE)–EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395, is … [Read more…]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that it will present updated data from the dose escalation phase of its ongoing Phase 1 trial of BCA101, a bifunctional antibody designed to target the TGF-β trap to … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS today announced officially joining the Roche Accelerator with the goal to tap into Roche’s global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai. “We are excited to become a member of the Roche Accelerator and to establish a closer connection with a … [Read more…]
Brandywine’s premier properties have implemented WellAir’s portfolio of IAQ solutions in elevators and select conference rooms to help improve and protect their indoor environments. STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today announced the implementation of its solutions in the elevator cabs throughout Brandywine’s entire Trophy Class of buildings … [Read more…]
Pregistry’s Latest Recruitment Brings Senior Executive Talent to the Team LOS ANGELES–(BUSINESS WIRE)–#CMO—Pregistry, a leader in the development and conduct of observational studies during pregnancy, announced today the appointment of Dr. Cheryl Renz as the company’s Chief Medical Officer (CMO). In this role, Dr. Renz will oversee medical and pharmacovigilance strategies for the rapidly growing … [Read more…]
– Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study – Preliminary efficacy data highlight XC001 potential for patients with refractory angina with no other treatment options – Treatment … [Read more…]
IRVINE, Calif.–(BUSINESS WIRE)–Today Viseon Inc. announced that it recently achieved over 1,000 U.S. Minimally Invasive Spine Surgery cases utilizing the Viseon MaxView Imaging Platform. MaxView is a state-of-the-art intraoperative imaging technology that enables a highly magnified unobstructed view of the surgical corridor and critical anatomy projected in real time onto operating room flat panel displays … [Read more…]
New funding will support ongoing clinical development of lead candidate, SBT101 for adrenomyeloneuropathy (AMN) Phase 1/2 study initiation of SBT101 expected in the second half of 2022 Pipeline development to continue, focused on spinal cord-related disorders PHILADELPHIA–(BUSINESS WIRE)–SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological … [Read more…]
